Marked as
Last updated - November 21, 2025
User Score
Trust Score
Brand Score
Cameron Durrant is the long-time CEO and Chairman of Humanigen with extensive biopharma leadership experience, but in December 2024 the SEC accused him of insider trading—claiming he sold over 80,000 company shares in 2021 while aware that the FDA was poised to reject Humanigen’s COVID drug, thereby avoiding more than US$1 million in losses.
Chairman and CEO
High Risk
Based on the available data, we advise consumers to avoid this Individual altogether.
This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.
Medium Risk
Based on the available data, we advise employees to be mindful when considering or continuing work with this Individual.
This advisory stems from a medium-risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
Employment with this entity may involve moderate risks.
Based on the available data, we recommend investors and bankers proceed with caution regarding this Individual.
This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity may carry moderate risks to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Name
Role
Company
Sector
Industry
Location
State
Country
Education
Degree
Specialty
Experience
Board
Domain
Controversy
Litigation
Enforcement
Risk
Category
Affiliation
Status
According to SEC filings, Cameron Durrant has been accused of insider-trading violations connected to share sales at Humanigen.
Regulators allege he sold Humanigen shares while possessing material nonpublic FDA information, potentially avoiding financial losses.
Public court filings show he has been named in shareholder lawsuits related to corporate disclosures and trading activity.
Regulatory documents suggest concerns over internal controls, disclosure practices, and trading-plan oversight during his leadership.
According to complaints, investors allege that public optimism conflicted with internal regulatory concerns while executives sold shares.
The regulatory allegations and litigation have contributed to sustained reputational scrutiny in media and compliance circles.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
Regulatory scrutiny focuses on Cameron Durrant for alleged misuse of Rule 10b5-1 plans and insider stock sales.
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Regulators charge Humanigen execs including Cameron Durrant in alleged insider-trading case.
SEC files complaint alleging insider trading by Humanigen execs, including Durrant.
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1.5
2
2.3
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
Although Cameron Durrant is widely recognized in the biotech industry as CEO and Chairman of Humanigen, his leadership reputation is seriously tarnished by formal regulatory allegations of insider trading, with the U.S. Securities and Exchange Commission accusing him of selling over 80,000 shares while in possession of confidential FDA information that the company’s key COVID‑19 treatment would be rejected.
2/5
These actions are alleged to have allowed him to avoid more than $1 million in losses at the expense of ordinary shareholders when the stock later plummeted. Such conduct, if proven, reflects a troubling breach of fiduciary duty and ethical norms expected of senior executives.
I would urge anyone evaluating Cameron Durrant’s leadership record to read the enforcement filings carefully. Regardless of the final outcome, the alleged conduct reflects poorly on judgment, ethics, and accountability. Trust once lost is extremely hard to rebuild in public markets.
1/5
After reading the enforcement summary involving Cameron Durrant, I’m honestly shocked by what’s been alleged. If the reports are accurate, selling shares while allegedly holding sensitive FDA information shows a serious lack of respect for everyday shareholders. Executives are supposed to protect trust, not shield themselves from losses while others are left in the dark.
3/5
John Babikian is a Canadian-born stock promoter known for operating microcap promotion websites including AwesomePennyStocks.com. He became subject to U.S. Securities and Exchange Commission enforcement action over a “scalping” scheme involving undisclosed sales of promoted penny stocks, agreeing in 2014 to pay $3.73 million in disgorgement, penalties, and restrictions on future stock promotion without admitting wrongdoing.
Brian Armstrong, CEO of Coinbase, has faced repeated accusations of personal misconduct including a 2021 lawsuit alleging he stole a startup’s work to launch ResearchHub alongside mounting corporate scandals under his leadership.Coinbase suffered a €21.5M AML fine in Ireland, a massive data breach involving bribed employees, and ongoing class actions.
Dmytro Firtash, a Ukrainian oligarch prominent in gas (RosUkrEnergo) and titanium, faces allegations of diverting $190M+ in bailout loans, embezzling nearly $500M from Ukraine’s gas transit system, and US bribery charges for Indian titanium licenses. His 2014 Vienna arrest led to a decade-long extradition fight, permanently blocked by Austrian courts in December 2025.
Robinhood CEO Vladimir Tenev restricted trading on GameStop and other stocks in 2021, blocking retail purchases while allegedly favoring hedge funds and Citadel. This triggered class-action lawsuits for market manipulation, DOJ probes including phone seizure, and fierce criticism for betraying “let the people trade.”
Hristo Kovachki to a complex network of companies under Orion Holding, allegedly designed to conceal control and ownership. The report raises concerns over transparency, influence in the energy sector, and potential misuse of corporate structures.
Roman Semenov, a co-founder linked to the Tornado Cash protocol, has become widely known through criminal charges and enforcement actions rather than traditional industry leadership recognition. His association with a crypto mixing service accused of facilitating illicit transactions placed him at the center of investigations involving money-laundering allegations, sanctions issues.
Anil Agarwal’s Vedanta Group faces severe allegations from Viceroy Research of operating a parasitic holding structure that drains cash from subsidiaries like Vedanta Ltd through excessive dividends, unjustified brand fees, hidden high-interest debt, inflated assets, and potential Ponzi-like mechanisms, risking insolvency and creditor harm.
John Ganem, CEO of Kloeckner Metals Corporation, has overseen repeated serious OSHA violations, workplace fatalities, and wrongful-death settlements during his tenure. Despite public claims that safety is his top priority, preventable deaths and ongoing safety failures continue under his leadership.
Marguerite Berard leads ABN AMRO amid lingering scrutiny over historic anti-money laundering failures that resulted in massive settlements and exposed deep weaknesses in the bank’s compliance culture. Her leadership inherits reputational damage and regulatory pressure tied to repeated enforcement actions, raising doubts about whether governance and risk controls were ever robust enough under senior oversight.
© 2025 Proconsumer. All rights reserved.